Standard and Poor's Raises Boston Scientific's Rating Outlook to Positive

PRNewswire NATICK, Mass. (NYSE:BSX)

NATICK, Mass., March 25 <u>PRNewswire-FirstCall</u>/ -- Boston Scientific Corporation today announced that Standard and Poor's Ratings Services has raised the Company's rating outlook to positive from negative, while affirming the Company's corporate credit rating at BB+.

The Standard and Poor's upgrade follows the Moody's actions of March 12 when it raised the Company's outlook to stable from negative.

Standard and Poor's said the revised rating outlook reflects: (1) the company's ongoing debt pay down over the past several years; (2) maintenance of its leading market share in the drug-eluting stent market in the face of increasing competition; and (3) prospects for (at a minimum) modest growth in cardiac rhythm management devices given recent, new product launches.

"We are pleased with the outlook upgrades by both Standard and Poor's and Moody's, which acknowledge the strengthening of our financial fundamentals, the improvements in our businesses, as well as the prospects and the progress we are making in driving profitable sales growth," said Sam Leno, Executive Vice President and Chief Financial Officer of Boston Scientific. "We will continue to focus on strengthening our profit margins, free cash flow, debt repayment and financial discipline."

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our financial position, debt repayment and cost-savings initiatives, our growth strategy, and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Paul Donovan 508-650-8541 (office) 508-667-5165 (mobile) Media Relations Boston Scientific Corporation

Larry Neumann 508-650-8696 (office) Investor Relations Boston Scientific Corporation

SOURCE: Boston Scientific Corporation

Web site: http://www.bostonscientific.com/

https://news.bostonscientific.com/standard-and-poors-rating-outlook-positive